Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.93% is 43% above its 5-year average of -24.25%, near the high end of its 5-year range (-48.70%–-13.19%).
22.33% above its 12-month average of -17.93%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.27%.
RETURN ON ASSETS (ROA)
-13.93%
RETURN ON ASSETS (ROA) AVG TTM
-17.93%
RETURN ON ASSETS (ROA) AVG 3Y
-26.92%
RETURN ON ASSETS (ROA) AVG 5Y
-24.25%
RETURN ON ASSETS (ROA) AVG 10Y
-22.70%
RETURN ON ASSETS (ROA) AVG 15Y
-19.47%
RETURN ON ASSETS (ROA) AVG 20Y
-32.55%
CURRENT VS TTM AVG
+22.33%
CURRENT VS 3Y AVG
+48.25%
CURRENT VS 5Y AVG
+42.57%
CURRENT VS 10Y AVG
+38.63%
CURRENT VS 15Y AVG
+28.44%
CURRENT VS 20Y AVG
+57.21%
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
+55.74%
vs the sector median at left
Standard BioTools Inc.
Market Cap
$288.39M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$287.37M
Return on Assets (ROA)
-17.87%
TTM Avg
-36.13%
3Y Avg
-48.35%
5Y Avg
-41.88%
Market Cap
$286.50M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$286.40M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$284.38M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$282.30M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$294.51M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$279.36M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$277.05M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Standard BioTools Inc. (LAB) | $288.39M | -13.93% | -17.93% | -26.92% | -24.25% |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.37M | -17.87% | -36.13% | -48.35% | -41.88% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $286.50M | -128.66% | -214.31% | -145.75% | -133.94% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -35.03% | -13.04% | -43.14% | -55.84% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.38M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.30M | -26.24% | -12.09% | -27.60% | -33.24% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $294.51M | -104.42% | -76.93% | -55.08% | -54.19% |
| Aurora Cannabis Inc. (ACB)vs › | $279.36M | -18.18% | -10.00% | -29.10% | -54.94% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | -5.36% | -34.75% | -39.14% | -23.69% |
| Benitec Biopharma Inc. (BNTC)vs › | $301.12M | -24.94% | -31.51% | -135.72% | -152.11% |
ROA
-13.9%
ROE
-16.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -13.19% |
| 2024-12-31 | -22.68% |
| 2023-12-31 | -23.11% |
| 2022-12-31 | -48.70% |
| 2021-12-31 | -21.52% |
| 2020-12-31 | -16.33% |
| 2019-12-31 | -24.47% |
| 2018-12-31 | -19.43% |
| 2017-12-31 | -21.07% |
| 2016-12-31 | -24.80% |
| 2015-12-31 | -14.37% |
| 2014-12-31 | -12.96% |
| 2013-12-31 | -13.53% |
| 2012-12-31 | -16.73% |
| 2011-12-31 | -28.33% |
| 2010-12-31 | -68.15% |
| 2009-12-31 | -59.49% |
| 2008-12-31 | -91.18% |
| 2007-12-31 | -46.46% |
| 2006-12-31 | -64.54% |
